Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07339735 | A Study of LY4064809 in Healthy Adult Participants | PHASE1 | COMPLETED | 24 | — | — | Jan 12, 2026 | Mar 19, 2026 | Apr 20, 2026 | 1 | United States |
PK: Cmax of LY4064809
PK: AUC of LY4064809
| Arm | Type | Description |
|---|---|---|
| LY4064809 Test | EXPERIMENTAL | LY4064809 test (Phase 3 formulation) formulation administered orally in one of two periods. |
| LY4064809 Reference | EXPERIMENTAL | LY4064809 reference (Phase 1 formulation) formulation administered orally in one of two periods. |
| Name | Type | Description |
|---|---|---|
| LY4064809 Test Formulation | DRUG | Administered orally |
| LY4064809 Reference Formulation | DRUG | Administered orally |
Inclusion Criteria: * Are healthy as determined by medical evaluation, including medical history, physical examination, vital signs, and electrocardiogram (ECG) at screening and admission. * Have clinical laboratory test results within the normal range * Have normal blood pressure and pulse rate or...